ALIVUS vs BIOFILCHEM: Stock Comparison
Alivus Life Sciences Limited vs Biofil Chemicals & Pharmaceuticals Limited
Live data: 28 July 2026, 4:08 PM IST • Source: NSE and company filings
Alivus Life Sciences Limited is the larger company by market capitalisation. Alivus Life Sciences Limited shows a higher dividend yield, faster revenue growth and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Side-by-side comparison of Alivus Life Sciences Limited and Biofil Chemicals & Pharmaceuticals Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | ALIVUS | BIOFILCHEM |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | ALIVUS | BIOFILCHEM |
|---|---|---|
| Live Price | ₹1,104.7 | ₹32.64 |
| Day Change | -2.45% | -0.55% |
| Volume | 30,434 | 4,048 |
| 52-Week High | ₹1,193.9 | ₹46.34 |
| 52-Week Low | ₹819 | ₹25.6 |
| Distance from 52W High | -7.47% | -29.56% |
Valuation
| Metric | ALIVUS | BIOFILCHEM |
|---|---|---|
| Market Cap | ₹13,552 Cr | ₹53 Cr |
| P/E Ratio | 23.98x | — |
| P/B Ratio | 4.06x | — |
| EPS | ₹45.92 | ₹1.71 |
| Book Value | ₹271.02 | ₹13.21 |
| Dividend Yield | 0.45% | 0% |
Growth
| Metric | ALIVUS | BIOFILCHEM |
|---|---|---|
| Revenue Growth (TTM YoY) | 6.1% | -9.3% |
| EPS Growth (TTM YoY) | 14.5% | 10.8% |
| Qtr Sales Growth | — | -9.34% |
| Qtr Profit Growth | — | 5% |
Profitability & Leverage
| Metric | ALIVUS | BIOFILCHEM |
|---|---|---|
| ROE | — | 13.8% |
| ROCE | — | 15.8% |
| Net Margin | 22.05% | 9.81% |
| Operating Margin | 31.4% | 2.29% |
| Debt to Equity | — | 0.14x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | ALIVUS | BIOFILCHEM |
|---|---|---|
| Promoter Holding | 74.87% | 46.79% |
| FII Holding | 5.54%▲ 0.25 pp | 0% |
| DII Holding | 7.18%▼ 0.1 pp | 0.08% |
| Public Holding | 12.41%▼ 0.15 pp | 53.13% |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Alivus Life Sciences Limited and Biofil Chemicals & Pharmaceuticals Limited.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.